State Street Increased Chemocentryx (CCXI) Stake by $12.08 Million; United States Cellular (USM)’s Sentiment Is 0.91

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

State Street Corp increased Chemocentryx Inc (NASDAQ:CCXI) stake by 293.31% reported in 2019Q2 SEC filing. State Street Corp acquired 1.34M shares as Chemocentryx Inc (NASDAQ:CCXI)’s stock declined 38.33%. The State Street Corp holds 1.80M shares with $16.74 million value, up from 457,546 last quarter. Chemocentryx Inc now has $391.44M valuation. The stock increased 3.86% or $0.25 during the last trading session, reaching $6.72. About 483,011 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since August 17, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

United States Cellular Corp (USM) investors sentiment decreased to 0.91 in Q1 2019. It’s down -0.45, from 1.36 in 2018Q4. The ratio fall, as 60 funds started new or increased stock positions, while 66 sold and decreased their positions in United States Cellular Corp. The funds in our database reported: 14.20 million shares, up from 13.85 million shares in 2018Q4. Also, the number of funds holding United States Cellular Corp in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 15 Reduced: 51 Increased: 42 New Position: 18.

Gamco Investors Inc. Et Al holds 0.71% of its portfolio in United States Cellular Corporation for 2.03 million shares. Gabelli Funds Llc owns 969,300 shares or 0.28% of their US portfolio. Moreover, Alpha Windward Llc has 0.26% invested in the company for 8,460 shares. The New York-based Quinn Opportunity Partners Llc has invested 0.25% in the stock. Acadian Asset Management Llc, a Massachusetts-based fund reported 829,713 shares.

United States Cellular Corporation provides wireless telecommunications services in the United States. The company has market cap of $3.02 billion. The Company’s wireless services include postpaid and prepaid service plans with voice, messaging, and data services; and smartphone messaging, data, and Internet services, which allow the customer to access the Web and social network sites, e-mail, text, picture, and video messaging, as well as to utilize GPS navigation, and browse and download various applications. It has a 21.65 P/E ratio. The firm also offers roaming services; machine to machine solutions and software applications in the areas of monitor and control, business automation/operations, communication, and asset management; wireless devices, such as handsets, tablets, mobile hotspots, home phones, and routers; and accessories comprising wireless basics, such as cases, screen protectors, chargers, and memory cards.

More notable recent United States Cellular Corporation (NYSE:USM) news were published by: Finance.Yahoo.com which released: “Here’s Why United States Cellular (NYSE:USM) Has A Meaningful Debt Burden – Yahoo Finance” on July 31, 2019, also Finance.Yahoo.com with their article: “The United States Cellular (NYSE:USM) Share Price Has Gained 20% And Shareholders Are Hoping For More – Yahoo Finance” published on June 11, 2019, Bizjournals.com published: “See inside the new U.S. Cellular Loft at Lambeau Field – Milwaukee Business Journal” on July 31, 2019. More interesting news about United States Cellular Corporation (NYSE:USM) were released by: Finance.Yahoo.com and their article: “All You Need To Know About United States Cellular Corporation’s (NYSE:USM) Financial Health – Yahoo Finance” published on May 01, 2019 as well as Businesswire.com‘s news article titled: “Consumers Rate U.S. Cellular Highest for Network Quality in the North Central Region in Latest J.D. Power Study – Business Wire” with publication date: July 24, 2019.

The stock increased 2.61% or $0.89 during the last trading session, reaching $34.97. About 319,467 shares traded or 33.27% up from the average. United States Cellular Corporation (USM) has risen 38.37% since August 17, 2018 and is uptrending. It has outperformed by 38.37% the S&P500. Some Historical USM News: 10/04/2018 – Fractus Files Patent Infringement Suit Against Telecom Giants AT&T, Verizon, T-Mobile and Sprint; 15/05/2018 – U.S. Cellular Presenting at JPMorgan Conference Tomorrow; 28/03/2018 U.S. Cellular to Offer New 9.7-inch iPad With Apple Pencil Support; 01/05/2018 – US Cellular 1Q EPS 52c; 10/05/2018 – U.S. Cellular Presenting at JPMorgan Conference May 16; 01/05/2018 – U.S. CELLULAR REAFFIRMS YR OPER REV., ADJ. EBITDA, CAPEX VIEWS; 16/05/2018 – UNITED STATES CELLULAR SAYS ON MAY 10, CO ENTERED INTO $300 MLN CREDIT AGREEMENT – SEC FILING; 01/05/2018 – US Cellular 1Q Rev $942M; 15/05/2018 – TDS and U.S. Cellular To Webcast Annual Meetings Of Shareholders; 01/05/2018 – US Cellular Backs 2018 Rev $3.85B-$4.05B

Investors sentiment increased to 1.44 in 2019 Q1. Its up 0.51, from 0.93 in 2018Q4. It is positive, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Legal & General Group Public Ltd Company has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 46,500 are owned by Alliancebernstein Lp. Carmignac Gestion owns 1.97M shares. Fernwood Inv Mgmt Ltd Liability Corporation has 10,000 shares. Acadian Asset Mgmt Ltd Liability Corporation reported 775,123 shares. Tiaa Cref Inv Management Ltd Liability Co holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 288,597 shares. Wells Fargo Mn holds 127,125 shares or 0% of its portfolio. State Common Retirement Fund accumulated 25,400 shares. Moreover, Alps Advisors has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Clarivest Asset Ltd Liability Co reported 51,400 shares. Swiss Retail Bank reported 0% stake. Arrowstreet Cap Partnership accumulated 324,748 shares. Fmr Ltd holds 0.01% or 5.77 million shares. Invesco, Georgia-based fund reported 148,988 shares. Bancshares Of Montreal Can owns 123,643 shares for 0% of their portfolio.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $391.44 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

State Street Corp decreased Caci Intl Inc (NYSE:CACI) stake by 164,333 shares to 620,841 valued at $127.02M in 2019Q2. It also reduced Mirati Therapeutics Inc (NASDAQ:MRTX) stake by 269,916 shares and now owns 1.14M shares. Boeing Co (NYSE:BA) was reduced too.

Among 2 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx has $2400 highest and $22 lowest target. $23’s average target is 242.26% above currents $6.72 stock price. ChemoCentryx had 4 analyst reports since March 12, 2019 according to SRatingsIntel. As per Tuesday, March 12, the company rating was maintained by H.C. Wainwright. The stock has “Buy” rating by FBR Capital on Wednesday, March 27.

United States Cellular Corporation (NYSE:USM) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *